Purchase this article with an account.
Y. Motomura, M. Miura, T. Iwasaki, H. Goto; Combination Photodynamic Therapy and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1900.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the therapeutic efficacy of combination photodynamic therapy (PDT) and intravitreal bevacizumab for polypoidal choroidal vasculopathy (PCV).
Combination of intravitreal bevacizumab (1.25 mg) and PDT was performed on 11 eyes of 11 Japanese patients (mean age 73.6 y) with PCV. Intravitreal bevacizumab and PDT were carried out every 4 weeks and 12 weeks, respectively, according to the optical coherence tomography findings. We retrospectively compared the best-corrected visual acuities (BCVA) of the combination therapy group with PDT monotherapy group (61 eyes of 61 Japanese patients, mean age 70.0 y).
Log MAR BCVA at baseline were -079 ± 0.58 in the combination therapy group and -074 ± 0.49 in the PDT monotherapy group. The difference in the logMAR BCVA at the baseline was not significant (P = 0.76). 12 months after treatment, the logMAR BCVA change from baseline in the combination therapy group (0.37 ± 0.59) was significantly better than the PDT monotherapy group (0.08 ± 0.40)(P = 0.041).
The improvement of BCVA was significantly better in the combination therapy group than in the PDT monotherapy group. Combination PDT and intravitreal bevacizumab was effective treatment for PCV.
This PDF is available to Subscribers Only